HAYWARD, Calif.--(BUSINESS WIRE)--IMPAX Laboratories, Inc. today announced that it met with representatives of the U.S. Food and Drug Administration (FDA) to review the results of its IPX056 clinical development program and discuss next steps in development leading to submission of a new drug application (NDA). IPX056 is an investigational extended-release formulation of baclofen, the drug of choice in the treatment of spasticity, which has the potential to offer improved control of symptoms and dosing convenience.
